Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.

Geusens P, Kendler DL, Fahrleitner-Pammer A, López-Romero P, Marin F

Calcified tissue international10 Mar 2020Cited by 6 (Europe PMC)

PMID32157334DOI10.1007/s00223-020-00683-6PepBankPUB-32157334

Publisher page PubMedAsk about this study

Summary

Vertebral fractures (VFx) occur most frequently in the mid-thoracic and thoraco-lumbar regions, which experience the highest mechanical loading along the spine. The prevalence and incidence of VFx by their location and severity, and their relationship with bone mineral density (BMD), are seldom reported in randomized clinical trial cohorts. The VERO trial randomized 1360 postmenopausal women with at least two moderate or one severe VFx to receive either teriparatide or risedronate for up to 24 months. In this post hoc analysis, we describe the centrally read distribution and severity of prevalent and incident VFx, and the association of their location with the baseline BMD. At baseline, 21.4% of all evaluable vertebral bodies had a prevalent VFx; most commonly at L₁, T₁₂, L₂ and T₁₁ (38.5%, 37.4%, 25.3% and 23.5% of patients, respectively). Patients with prevalent VFx only at T₁₂/L₁ showed a higher baseline BMD compared to patients with VFx at other levels. At month 24, 100 patients had 126 incident VFx (teriparatide: 35; risedronate: 91). The most frequent incident VFx occurred at T₁₂ (n = 17, 1.6% of patients), followed by L₁ and T₁₁ (n = 14, 1.3% both). The frequency of incident VFx was lower at all vertebral levels in patients given teriparatide. These results confirm prior reports that VFx occurs more frequently at mid-thoracic and thoraco-lumbar regions of the spine. Patients with these VFx locations have higher BMD than those who fracture at other sites, suggesting a role for mechanical stress in the etiology of VFx. Teriparatide is superior to risedronate in the prevention of VFx at these common fracture locations.Trial registration ClinicalTrials.gov Identifier: NCT01709110.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, incident vertebral fractures numbered 35 with teriparatide and 91 with risedronate at month 24.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide had fewer new vertebral fractures than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIncident vertebral fracture count
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 24 monthsAs given in this study (human).
Measurements
Incident vertebral fractures
35 fractures
teriparatide at month 24
Incident vertebral fractures
91 fractures
risedronate at month 24
Source sentences
Summary
At month 24, 100 patients had 126 incident VFx (teriparatide: 35; risedronate: 91).
2 context sentences(design, population, supporting numbers)
Summary · context
The VERO trial randomized 1360 postmenopausal women with at least two moderate or one severe VFx to receive either teriparatide or risedronate for up to 24 months.
Summary · context
In this post hoc analysis, we describe the centrally read distribution and severity of prevalent and incident VFx, and the association of their location with the baseline BMD.
Show in the study text Report a problemFND-3215733401
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with vertebral fractures, incident fracture frequency was lower at all vertebral levels with teriparatide than risedronate.
In plain wordsIn postmenopausal women with vertebral fractures, teriparatide had fewer new fractures at all vertebral levels than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIncident vertebral fracture frequency by vertebral level
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 24 monthsAs given in this study (human).
Source sentences
Summary
The frequency of incident VFx was lower at all vertebral levels in patients given teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
The VERO trial randomized 1360 postmenopausal women with at least two moderate or one severe VFx to receive either teriparatide or risedronate for up to 24 months.
Summary · context
In this post hoc analysis, we describe the centrally read distribution and severity of prevalent and incident VFx, and the association of their location with the baseline BMD.
Show in the study text Report a problemFND-3215733402

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In the pooled teriparatide-versus-risedronate trial cohort, prevalent fractures affected 21.4% of evaluable vertebral bodies and clustered at thoracolumbar levels.
In plain wordsIn the pooled teriparatide-versus-risedronate trial cohort, existing vertebral fractures clustered near the junction of the thoracic and lumbar spine.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableBaseline vertebral fracture prevalence and distribution
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Prevalent vertebral fractures
21.4%
all evaluable vertebral bodies
Prevalent fracture at L1
38.5%
patients
Prevalent fracture at T12
37.4%
patients
Prevalent fracture at L2
25.3%
patients
Prevalent fracture at T11
23.5%
patients
Source sentences
Summary
At baseline, 21.4% of all evaluable vertebral bodies had a prevalent VFx; most commonly at L₁, T₁₂, L₂ and T₁₁ (38.5%, 37.4%, 25.3% and 23.5% of patients, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The VERO trial randomized 1360 postmenopausal women with at least two moderate or one severe VFx to receive either teriparatide or risedronate for up to 24 months.
Summary · context
In this post hoc analysis, we describe the centrally read distribution and severity of prevalent and incident VFx, and the association of their location with the baseline BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3215733403
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In the pooled teriparatide-versus-risedronate cohort, baseline BMD was higher in patients with prevalent fractures only at T12/L1 than other levels.
In plain wordsIn the pooled teriparatide-versus-risedronate cohort, baseline bone density was higher with fractures only at T12/L1 than at other levels.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBaseline BMD by prevalent fracture location
Study
n: not reported in source
Comparator
Patients with fractures at other levels
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Patients with prevalent VFx only at T₁₂/L₁ showed a higher baseline BMD compared to patients with VFx at other levels.
2 context sentences(design, population, supporting numbers)
Summary · context
The VERO trial randomized 1360 postmenopausal women with at least two moderate or one severe VFx to receive either teriparatide or risedronate for up to 24 months.
Summary · context
In this post hoc analysis, we describe the centrally read distribution and severity of prevalent and incident VFx, and the association of their location with the baseline BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3215733404
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In the pooled teriparatide-versus-risedronate cohort, incident fractures occurred most frequently at T12, followed by L1 and T11.
In plain wordsIn the pooled teriparatide-versus-risedronate cohort, new vertebral fractures occurred most frequently at T12, followed by L1 and T11.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicablePooled incident vertebral fracture distribution
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Incident fractures at T12
17 fractures
pooled cohort
Patients with incident fractures at T12
1.6%
pooled cohort
Incident fractures at L1
14 fractures
pooled cohort
Incident fractures at T11
14 fractures
pooled cohort
Patients with incident fractures at L1
1.3%
pooled cohort
Patients with incident fractures at T11
1.3%
pooled cohort
Source sentences
Summary
The most frequent incident VFx occurred at T₁₂ (n = 17, 1.6% of patients), followed by L₁ and T₁₁ (n = 14, 1.3% both).
2 context sentences(design, population, supporting numbers)
Summary · context
The VERO trial randomized 1360 postmenopausal women with at least two moderate or one severe VFx to receive either teriparatide or risedronate for up to 24 months.
Summary · context
In this post hoc analysis, we describe the centrally read distribution and severity of prevalent and incident VFx, and the association of their location with the baseline BMD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3215733405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01709110

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Eli Lilly and Companyn = 1,366Oct 2012 to Jul 2016

Postmenopausal Osteoporosis

Trial page ClinicalTrials.govUpdated 23 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.